Crucial clinical events for the smaller players
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Biotech’s key fourth-quarter data
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Oncology the focus for big pharma catalysts
The fourth quarter will see key immunotherapy data from Astrazeneca and Merck, while full details on Glaxo's anaemia pill, daprodustat, are expected.
Esmo 2021 – Astra coasts towards a new lung cancer combo
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
Esmo 2021 – colorectal cancer could be Mirati’s golden ticket
Adagrasib looks better than Amgen’s Lumakras, which could explain why Mirati has been dragging its heels in lung cancer.
Covid-19 research efforts slow
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
Esmo 2021 – the jury remains out on CDK7 inhibition
Clinical data on Carrick’s samuraciclib and Syros’s SY-5609 show that this mechanism remains a work in progress.
